Compare · MO vs NAGE
MO vs NAGE
Side-by-side comparison of Altria Group Inc. (MO) and Niagen Bioscience Inc. (NAGE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MO and NAGE operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- MO is the larger of the two at $113.66B, about 439.3x NAGE ($258.7M).
- NAGE has been more active in the news (8 items in the past 4 weeks vs 2 for MO).
- MO has more recent analyst coverage (21 ratings vs 1 for NAGE).
- Company
- Altria Group Inc.
- Niagen Bioscience Inc.
- Price
- -
- -
- Market cap
- $113.66B
- $258.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 2
- 8
- Recent ratings
- 21
- 1
Altria Group Inc.
Altria Group, Inc., through its subsidiaries, manufactures and sells cigarettes, oral tobacco products, and wine in the United States. It offers cigarettes primarily under the Marlboro brand; cigars principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. The company also produces and sells varietal and blended table wines, and sparkling wines under the Chateau Ste. Michelle and 14 Hands names; and imports and markets Antinori, Torres, and Villa Maria Estate wines, as well as Champagne Nicolas Feuillatte in the United States. In addition, it provides finance leasing services primarily in transportation, power generation, real estate, and manufacturing equipment industries. The company sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.
Latest MO
- Altria Announces Arrangement with Philip Morris International to Enhance Operational Efficiency
- Philip Morris International Announces Contract Manufacturing Collaboration with Altria
- SEC Form 10-Q filed by Altria Group Inc.
- Altria Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Altria Reports 2026 Second-Quarter and First-Half Results; Narrows 2026 Full-Year Earnings Guidance
- Cadiz Inc. Announces CFO Succession
- BTIG Research initiated coverage on Altria
- Altria to Host Webcast of 2026 Second-Quarter and First-Half Results
- UBS reiterated coverage on Altria with a new price target
- SEC Form 11-K filed by Altria Group Inc.
Latest NAGE
- Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit
- Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam’s Club
- Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference
- Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence
- SEC Form 10-Q filed by Niagen Bioscience Inc.
- Niagen Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
- Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
- Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biological Aging
- Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference